Market Research Logo

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.

Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsenic, and infections. Treatment includes removing the bladder or treating the bladder with radiation and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Muscle Invasive Bladder Cancer (MIBC).

Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Muscle Invasive Bladder Cancer (MIBC) Overview
Therapeutics Development
Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview
Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Investigation by Universities/Institutes
Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies
Muscle Invasive Bladder Cancer (MIBC) - Products under Investigation by Universities/Institutes
Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development
Argos Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Cold Genesys Inc
F. Hoffmann-La Roche Ltd
MedImmune LLC
Oncolytics Biotech Inc
Sillajen Biotherapeutics
Taris Biomedical LLC
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
atezolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1775 + durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erlotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guadecitabine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTG-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexastimogene devacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rocapuldencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects
Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones
Featured News & Press Releases
Jul 13, 2016: TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Muscle-Invasive Bladder Cancer
Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report